{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:50:14Z","timestamp":1769525414716,"version":"3.49.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117438","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T19:51:54Z","timestamp":1761076314000},"page":"117438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P4","title":["Inhibiting Cytosine-Adenine-Guanine (CAG) repeat expansions as a therapeutic strategy for Huntington\u2019s disease"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6453-7593","authenticated-orcid":false,"given":"Raymond J.","family":"Winquist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Church","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5940","key":"10.1016\/j.bcp.2025.117438_b0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/306234a0","article-title":"A polymorphic DNA marker genetically linked to Huntington's disease","volume":"306","author":"Gusella","year":"1983","journal-title":"Nat"},{"issue":"6","key":"10.1016\/j.bcp.2025.117438_b0010","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"The Huntington's Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117438_b0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ng0893-387","article-title":"Trinucleotide repeat length instability and age of onset in Huntington's disease","volume":"4","author":"Duyao","year":"1993","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.bcp.2025.117438_b0020","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/hmg\/2.10.1547","article-title":"Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15","volume":"2","author":"Stine","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2025.117438_b0025","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/ng0494-409","article-title":"Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm","volume":"6","author":"Telenius","year":"1994","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.bcp.2025.117438_b0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mrdd.1022","article-title":"Juvenile onset Huntington's disease\u2013clinical and research perspectives","volume":"7","author":"Nance","year":"2001","journal-title":"Ment. Retard. Dev. Disabl. Res. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2025.117438_b0035","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1006\/exnr.1998.6919","article-title":"Regional specificity of brain atrophy in Huntington's disease","volume":"154","author":"Halliday","year":"1998","journal-title":"Exp. Neurol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117438_b0040","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington\u2019s disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117438_b0045","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/0896-6273(95)90106-X","article-title":"CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain","volume":"15","author":"Aronin","year":"1995","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.bcp.2025.117438_b0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2025.117438_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.628010","article-title":"D1R- and D2R-medium-sized spiny neurons diversity: insights into striatal vulnerability to Huntington's Disease mutation","volume":"15","author":"Bergonzoni","year":"2021","journal-title":"Front. Cell. Neurosci."},{"issue":"24","key":"10.1016\/j.bcp.2025.117438_b0060","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1093\/hmg\/ddg352","article-title":"Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis","volume":"12","author":"Kennedy","year":"2003","journal-title":"Hum. Mol. Genet."},{"issue":"10","key":"10.1016\/j.bcp.2025.117438_b0065","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/hmg\/ddm054","article-title":"The US-Venezuela Collaborative Research Group, Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain","volume":"16","author":"Shelbourne","year":"2007","journal-title":"Hum. Mol. Genet."},{"issue":"9","key":"10.1016\/j.bcp.2025.117438_b0070","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1073\/pnas.0800048105","article-title":"DNA instability in postmitotic neurons","volume":"105","author":"Gonitel","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"16","key":"10.1016\/j.bcp.2025.117438_b0075","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1093\/hmg\/ddp242","article-title":"Somatic expansion of the Huntington\u2019s disease CAG repeat in the brain is associated with an earlier age of disease onset","volume":"18","author":"Swami","year":"2009","journal-title":"Hum. Mol. Gen."},{"key":"10.1016\/j.bcp.2025.117438_b0080","doi-asserted-by":"crossref","unstructured":"M. Ciosi, A. Maxwell, S.A. Cumming, D.J.H. Moss, A.M. Alshammari, M.D. Flower, A.Durr, B.R. Leavitt, R.A.C. Roos, TRACK-HD team, Enroll-HD team, P, Holmans, L. Jones, D.R. Langbehn, S. Kwak, S.J. Tabrizi, D.G. Mockton, (2019) A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes, EBioMedicine (48) 568\u2013580, doi:10.1016\/j.ebiom.2019.09.020.","DOI":"10.1016\/j.ebiom.2019.09.020"},{"issue":"3","key":"10.1016\/j.bcp.2025.117438_b0085","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41588-024-01653-6","article-title":"Cell-type-specific CAG repeat expansions and toxicity of mutant Huntingtin in human striatum and cerebellum","volume":"56","author":"Matlik","year":"2024","journal-title":"Nat. Gen"},{"key":"10.1016\/j.bcp.2025.117438_b0090","doi-asserted-by":"crossref","unstructured":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium, J.-M. Lee, Z.L. McLean, K. Correia, J.W. Shin, S. Lee, J.-H. Jang, Y. Lee, K.-H. Kim, D.E. Choi, J.D. Long, D. Lucente, I.S. Seong, R.M. Pinto, J.V. Giordano, J.S. Mysore, J. Siciliano, E. Elezi, J. Ruliera, T. Gillis, V.C. Wheeler, M.E., MacDonald, J.F. Gusella, A. Gatseva, M. Ciosi, V. Lomeikaite, H. Loay, D.G. Monckton, C. Wills, T.H. Massey, L. Jones, P, Holmans, S. Kwak, C. Sampaio, M. Orth, G.B. Landwehrmeyer, J.S. Paulsen, E.R. Dorsey, R.H. Myers, Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease reveal shared and tissue-specific effects. bioRxiv (2024) Jun 18:2024.06-10-597797, doi:10.1101\/2024.06.10.597797.","DOI":"10.1101\/2024.06.10.597797"},{"issue":"3","key":"10.1016\/j.bcp.2025.117438_b0095","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.cell.2024.11.038","article-title":"Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease","volume":"188","author":"Handsaker","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117438_b0100","doi-asserted-by":"crossref","unstructured":"GeM HD Consortium, Identification of genetic factors that modify clinical onset of Huntington\u2019s Disease, Cell 162, (3) (2015) 516-526, https:\/\/doi : 10.1016\/j.cell.2015.07.003.","DOI":"10.1016\/j.cell.2015.07.003"},{"issue":"4","key":"10.1016\/j.bcp.2025.117438_b0105","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","article-title":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium. CAG repeat not polyglutamine length determines timing of Huntington\u2019s Disease onset","volume":"178","year":"2019","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bcp.2025.117438_b0110","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","article-title":"Identification of genetic variants associated with Huntington\u2019s disease progression: a genome-wide association study","volume":"16","author":"Moss","year":"2017","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.bcp.2025.117438_b0120","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrg1689","article-title":"Repeat instability: mechanisms of dynamic mutations","volume":"6","author":"Pearson","year":"2005","journal-title":"Nat. Rev. Genet."},{"issue":"4","key":"10.1016\/j.bcp.2025.117438_b0115","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/70598","article-title":"Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice","volume":"23","author":"Manley","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2025.117438_b0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JHD-200438","article-title":"DNA mismatch repair and its role in Huntington\u2019s Disease","volume":"10","author":"Iyera","year":"2021","journal-title":"J. Huntingtons Dis"},{"key":"10.1016\/j.bcp.2025.117438_b0130","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1342::AID-CNCR33>3.0.CO;2-3","article-title":"Significantly lower incidence of cancer among patients with Huntington disease","volume":"86","author":"S\u00f8rensen","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2025.117438_b0135","article-title":"Blocking somatic repeat expansion and lowering huntingtin via RNA interference synergize to prevent Huntington\u2019s disease pathogenesis in mice","volume":"25","author":"Belgrad","year":"2025","journal-title":"bioRxiv [Preprint]"},{"issue":"2","key":"10.1016\/j.bcp.2025.117438_b0140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/18796397251337000","article-title":"Huntington's disease clinical trials update: March 2025","volume":"4","author":"Farag","year":"2025","journal-title":"J. Huntingtons Dis"},{"issue":"1","key":"10.1016\/j.bcp.2025.117438_b0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/JHD-200445","article-title":"What is the pathogenic CAG expansion length in Huntington's disease?","volume":"10","author":"Donaldson","year":"2021","journal-title":"J Huntingtons Dis."},{"key":"10.1016\/j.bcp.2025.117438_b0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JHD-200427","article-title":"Huntington\u2019s Disease pathogenesis: two sequential components","volume":"10","author":"Hong","year":"2021","journal-title":"J. Huntingtons Dis."},{"issue":"1","key":"10.1016\/j.bcp.2025.117438_b0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration","volume":"23","author":"Hodgson","year":"1999","journal-title":"Neuron"},{"issue":"21","key":"10.1016\/j.bcp.2025.117438_b0160","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.21-21-08473.2001","article-title":"Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice","volume":"21","author":"Li","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2025.117438_b0165","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s Disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."},{"issue":"5334","key":"10.1016\/j.bcp.2025.117438_b0170","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bcp.2025.117438_b0175","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ng0896-442","article-title":"Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract","volume":"13","author":"Goldberg","year":"1996","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.bcp.2025.117438_b0180","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1531-8249(199912)46:6<842::AID-ANA6>3.0.CO;2-O","article-title":"Huntington aggregates may not predict neuronal death in Huntington's disease","volume":"46","author":"Kuemmerle","year":"1999","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117438_b0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0092-8674(00)81782-1","article-title":"Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions","volume":"95","author":"Saudou","year":"1998","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bcp.2025.117438_b0190","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/MCB.22.5.1277-1287.2002","article-title":"Interaction of Huntington disease protein with transcriptional activator Sp1","volume":"22","author":"Li","year":"2002","journal-title":"Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.bcp.2025.117438_b0195","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1111\/j.1460-9568.2006.04871.x","article-title":"Huntingtin inclusions do not down-regulate specific genes in the R6\/2 Huntington's disease mouse","volume":"23","author":"Sadri-Vakili","year":"2006","journal-title":"Eur. J. Neurosci."},{"issue":"5","key":"10.1016\/j.bcp.2025.117438_b0200","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.bcp.2025.117438_b0205","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/exnr.1996.6400","article-title":"Antisense gene therapy for neurodegenerative disease?","volume":"144","author":"Haque","year":"1997","journal-title":"Exp. Neurol."},{"issue":"23","key":"10.1016\/j.bcp.2025.117438_b0210","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMc2300400","article-title":"GENERATION HD1 INVESTIGATORS, Tominersen in adults with manifest Huntington's Disease","volume":"389","author":"McColgan","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.117438_b0215","doi-asserted-by":"crossref","unstructured":"C.G. Keller, Y. Shin, A.M. Monteys, N. Renaud, M. Beibel, N. Teider, T. Peters, T. Faller, S. St-Cyr, J. Knehr, G. Roma, A. Reyes, M. Hild, D. Lukashev, D. Theil, N.D.B. Borowsky, R. Dolmetsch, B.L. Davidson, J.-H. Cha, R. Sivasankaran, An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Nat. Comm. 13 (1) (2022) 1150- Mar 3;13(1):1150, doi:10.1038\/s41467-022-28653-6.","DOI":"10.1038\/s41467-022-28653-6"},{"key":"10.1016\/j.bcp.2025.117438_b0220","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1111\/bcp.16202","article-title":"Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: a first-in-human study","volume":"90","author":"Gao","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2025.117438_b0225","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1093\/brain\/awac241","article-title":"Alternative processing of human HTT mRNA with implications for Huntington's disease therapeutics","volume":"145","author":"Fienko","year":"2022","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.bcp.2025.117438_b0230","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117438_b0235","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","article-title":"Current clinical applications of AAV-mediated gene therapy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2025.117438_b0240","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","article-title":"Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease","volume":"25","author":"Zeitler","year":"2019","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117438_b0245","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2478\/jtim-2023-0142","article-title":"Latest advances on new promising molecular-based therapeutic approaches for Huntington's disease","volume":"12","author":"Cheng","year":"2024","journal-title":"J Translational Internal Med"},{"issue":"2","key":"10.1016\/j.bcp.2025.117438_b0250","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40263-024-01139-3","article-title":"Huntington Study Group\/ARC-HD Investigators and Coordinators, Safety and efficacy of deutetrabenazine at high versus lower daily dosages in the ARC-HD study to treat chorea in Huntington Disease","volume":"39","author":"Frank","year":"2025","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.bcp.2025.117438_b0255","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1086\/378133","article-title":"A genome scan for modifiers of age at onset in Huntington disease: the HD MAPS study","volume":"73","author":"Li","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"17","key":"10.1016\/j.bcp.2025.117438_b0260","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/hmg\/9.17.2539","article-title":"Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease?","volume":"9","author":"Kennedy","year":"2000","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.bcp.2025.117438_b0265","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ajhg.2019.04.007","article-title":"Length of uninterrupted CAG, independent of polyglutamine size, results in increased somatic instability, hastening onset of huntington disease","volume":"104","author":"Wright","year":"2019","journal-title":"Am. J. Hum. Gen."},{"issue":"3","key":"10.1016\/j.bcp.2025.117438_b0270","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41591-024-03424-6","article-title":"Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington\u2019s disease decades before clinical motor diagnosis","volume":"31","author":"Scahill","year":"2025","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bcp.2025.117438_b0275","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"Huntington\u2019s Disease Regulatory Science Consortium (HD-RSC), A biological classification of Huntington\u2019s disease: the Integrated Staging System","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117438_b0280","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41593-022-01033-5","article-title":"Exome sequencing of individuals with Huntington\u2019s disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset","volume":"25","author":"McAllister","year":"2022","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117438_b0285","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/cr.2007.115","article-title":"Mechanisms and functions of DNA mismatch repair","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res."},{"issue":"9","key":"10.1016\/j.bcp.2025.117438_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109649","article-title":"FAN1 controls mismatch repair complex assembly via MLH1 retention to stabilize CAG repeat expansion in Huntington's disease","volume":"36","author":"Goold","year":"2021","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.bcp.2025.117438_b0295","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1074\/jbc.M609989200","article-title":"Characterization of the interactome of the human MutL homologues MLH1, PMS1, and PMS2","volume":"282","author":"Cannavo","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2025.117438_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003930","article-title":"Mismatch repair genes Mlh1 and Mlh3 modify CAG instability in Huntington\u2019s disease mice: genome-wide and candidate approaches","volume":"9","author":"Pinto","year":"2013","journal-title":"PLoS Genet."},{"issue":"2","key":"10.1016\/j.bcp.2025.117438_b0305","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41588-024-02054-5","article-title":"In vivo CRISPR-Cas9 genome editing in mice identifies genetic modifiers of somatic CAG repeat instability in Huntington\u2019s disease","volume":"57","author":"Pinto","year":"2025","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.bcp.2025.117438_b0310","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/70598","article-title":"Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice","volume":"23","author":"Manley","year":"1999","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.bcp.2025.117438_b0315","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/hmg\/ddg056","article-title":"Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum","volume":"12","author":"Wheeler","year":"2003","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.bcp.2025.117438_b0320","first-page":"1544","article-title":"Distinct mismatch-repair complex genes set neuronal CAG-repeat expansion rate to drive selective pathogenesis in HD","volume":"188","author":"Wang","year":"2025","journal-title":"mice"},{"issue":"5","key":"10.1016\/j.bcp.2025.117438_b0325","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/brain\/awae063","article-title":"A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease","volume":"147","author":"Aldous","year":"2024","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.bcp.2025.117438_b0335","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.ymthe.2023.09.016","article-title":"Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington\u2019s disease","volume":"31","author":"O'Reilly","year":"2023","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.117438_b0340","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41598-024-52667-3","article-title":"Dose-dependent reduction of somatic expansions but not Htt aggregates by di-valent siRNA-mediated silencing of MSH3 in HdhQ111 mice","volume":"14","author":"Driscoll","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117438_b0345","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn4600","article-title":"Antisense oligonucleotide-mediated MSH3 suppression reduces somatic CAG repeat expansion in Huntington's disease iPSC-derived striatal neurons","volume":"17","author":"Bunting","year":"2025","journal-title":"Sci. Transl. Med."},{"issue":"18","key":"10.1016\/j.bcp.2025.117438_b0350","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1093\/hmg\/ddaa196","article-title":"Promotion of somatic CAG repeat expansion by Fan1 knock-out in Huntington's disease knock-in mice is blocked by Mlh1 knock-out","volume":"29","author":"Loupe","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2025.117438_b0355","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ajhg.2022.03.004","article-title":"Genetic modifiers of Huntington disease differentially influence motor and cognitive domains","volume":"109","author":"Lee","year":"2022","journal-title":"Am. J. Hum. Gen."},{"issue":"6","key":"10.1016\/j.bcp.2025.117438_b0360","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.neuron.2023.12.009","article-title":"Selective vulnerability of layer 5a corticostriatal neurons in Huntington's disease","volume":"112","author":"Pressl","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2025.117438_b0365","article-title":"Identification of orthosteric inhibitors of MutS\u03b2 ATPase function","author":"Brace","year":"2024","journal-title":"Chem Rxiv"},{"issue":"1","key":"10.1016\/j.bcp.2025.117438_b0330","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nbd.2008.09.014","article-title":"Intergenerational and striatal CAG repeat instability in Huntington's disease knock-in mice involve different DNA repair genes","volume":"33","author":"Dragileva","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"16","key":"10.1016\/j.bcp.2025.117438_b0370","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2322924121","article-title":"Posttranscriptional regulation of FAN1 by miR- 124\u20133p at rs3512 underlies onset- delaying genetic modification in Huntington\u2019s disease","volume":"121","author":"Kim","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"9","key":"10.1016\/j.bcp.2025.117438_b0375","first-page":"11060","article-title":"MSH3 rs26279 polymorphism increases cancer risk: a meta-analysis","volume":"8","author":"Miao","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117438_b0380","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3892\/ijmm.2017.3044","article-title":"Inactivation of MSH3 by promoter methylation correlates with primary tumor stage in nasopharyngeal carcinoma","volume":"40","author":"Ni","year":"2017","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117438_b0385","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41698-024-00511-2","article-title":"Compound heterozygous MSH3 germline variants and associated tumor somatic DNA mismatch repair dysfunction","volume":"8","author":"Koi","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117438_b0390","doi-asserted-by":"crossref","first-page":"8782","DOI":"10.1007\/s12035-025-04813-9","article-title":"Nuclear microRNA-1 promotes neurite outgrowth after spinal cord injury by enhancing Cttn transcription","volume":"62","author":"Yang","year":"2025","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117438_b0395","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.neuron.2022.10.031","article-title":"The miR-124-AMPAR pathway connects polygenic risks with behavioral changes shared between schizophrenia and bipolar disorder","volume":"111","author":"Namkung","year":"2023","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.bcp.2025.117438_b0400","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s13167-024-00368-2","article-title":"Unraveling progression subtypes in people with Huntington's disease","volume":"15","author":"Raschka","year":"2024","journal-title":"EPMA J."},{"key":"10.1016\/j.bcp.2025.117438_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2024.103650","article-title":"Prognostic enrichment for early-stage Huntington's disease: an explainable machine learning approach for clinical trial","volume":"43","author":"Ghofrani-Jahromi","year":"2024","journal-title":"Neuroimage Clin."},{"issue":"1","key":"10.1016\/j.bcp.2025.117438_b0410","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1186\/s12864-024-10855-5","article-title":"Leveraging explainable deep learning methodologies to elucidate the biological underpinnings of Huntington's disease using single-cell RNA sequencing data","volume":"25","author":"Gao","year":"2024","journal-title":"BMC Genomics"},{"key":"10.1016\/j.bcp.2025.117438_b0415","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.cell.2022.02.015","article-title":"Spatial CRISPR genomics identifies regulators of the tumor microenvironment","volume":"185","author":"Dhainaut","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117438_b0420","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1126\/science.aax6234","article-title":"Massively multiplex chemical transcriptomics at single-cell resolution","volume":"367","author":"Srivatsan","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2025.117438_b0425","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1038\/s41467-024-47485-0","article-title":"Splice modulators target PMS1 to reduce somatic expansion of the Huntington's disease-associated CAG repeat","volume":"15","author":"McLean","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T01:25:48Z","timestamp":1769477148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225007038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":85,"alternative-id":["S0006295225007038"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117438","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibiting Cytosine-Adenine-Guanine (CAG) repeat expansions as a therapeutic strategy for Huntington\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117438"}}